PD-L1 expression in triple-negative breast cancer: a cross-sectional study in a Polish population

Łukasz Szylberg; Ewa Antoniewicz; Wojciech Olszewski; Adam Kowalewski; Marek Zdrenka; Beata Dziekan; Matthew Ibbs; Violetta Filas; Andrzej Marszałek

doi:10.5114/pjp.2020.103710

eISSN: 2084-9869
ISSN: 1233-9687

Polish Journal of Pathology

Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

4/2020
vol. 71

Send email

Copy url:

abstract:

Original paper

PD-L1 expression in triple-negative breast cancer: a cross-sectional study in a Polish population

Łukasz Szylberg

^{1, 2}

,

Ewa Antoniewicz

³

,

Wojciech Olszewski

⁴

,

Adam Kowalewski

^{1, 2}

,

Marek Zdrenka

¹

,

Beata Dziekan

³

,

Matthew Ibbs

³

,

Violetta Filas

³

,

Andrzej Marszałek

³

Department of Tumor Pathology and Pathomorphology, Oncology Center, Prof. Franciszek £ukaszczyk Memorial Hospital, Bydgoszcz, Poland
Chair of Clinical Pathomorphology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland
Chair and Department of Oncologic Pathology and Prophylaxis, Greater Poland Cancer Center, Poznañ University of Medical Sciences and Department of Oncologic Pathology, Poznan, Poland
Department of Pathology, Maria Sk³odowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland

Pol J Pathol 2020; 71 (4): 301-306

DOI: https://doi.org/10.5114/pjp.2020.103710

Online publish date: 2021/02/22

View full text Get citation

PlumX metrics:

Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast carcinomas and represents an aggressive variant with a high mortality rate. PD-L1 is a protein that plays a pivotal role in suppressing the adaptive immune system. It has become a central target of the immunotherapy approach. Determining the PD-L1 status can identify TNBC patients who may benefit from targeted therapy. This study was performed to estimate the prevalence of PD-L1 expression among Polish TNBC patients. A total of 123 patients with TNBC were tested for PD-L1 expression using immunohistochemical studies. The PD-L1-positive tumors were found in 55 patients (45%), while PD-L1-negative tumors were found in 68 patients (55%). The PD-L1 positive tumors included 17 patients (31%) with the expression covering up to 1% of tumor area, 23 patients (42%) covering 2-5%, 8 patients (14%) covering 6-10% and 7 patients (13%) covering more than 10% of tumor area. The PD-L1 negative tumors included 17 patients (25%) with the expression covering less than 1% of tumor area and 51 patients (75%) with a complete lack of expression. There were no significant differences between the groups with different status of PD-L1 and the clinical tumor and lymph node stages as well as the patients’ age.

keywords:

PD-L1 expression in triple-negative breast cancer: a cross-sectional study in a Polish population

Łukasz Szylberg 1, 2 , Ewa Antoniewicz 3 , Wojciech Olszewski 4 , Adam Kowalewski 1, 2 , Marek Zdrenka 1 , Beata Dziekan 3 , Matthew Ibbs 3 , Violetta Filas 3 , Andrzej Marszałek 3

TNBC, PD-L1, breast cancer, triple negative

Łukasz Szylberg

^{1, 2}

,

Ewa Antoniewicz

³

,

Wojciech Olszewski

⁴

,

Adam Kowalewski

^{1, 2}

,

Marek Zdrenka

¹

,

Beata Dziekan

³

,

Matthew Ibbs

³

,

Violetta Filas

³

,

Andrzej Marszałek

³